utilized patient-derived non-small cell LCOs to explore drug resistance and found that elevated expression of tumor CD73 in patients with EGFR mutation contributes to the immunologically quiescent microenvironment of EGFR-mutant NSCLC, leading to immune checkpoint therapy resistance (90). Here, EGFR is linked to non-small cell lung carcinoma.